MARKET

RETA

RETA

Reata Pharmaceut
NASDAQ
25.04
-0.24
-0.95%
Opening 13:32 09/29 EDT
OPEN
25.06
PREV CLOSE
25.28
HIGH
25.47
LOW
24.20
VOLUME
296.09K
TURNOVER
4.14M
52 WEEK HIGH
114.80
52 WEEK LOW
18.47
MARKET CAP
913.87M
P/E (TTM)
-2.9932
1D
5D
1M
3M
1Y
5Y
AMRS, ADPT and RETA are among after hour movers
Gainers: Cognex  (CGNX) +9%. Lesaka Technologies (<a href...
Seekingalpha · 09/19 21:32
Why Is Kodiak Sciences Inc. (KOD) Down 23.8% Since Last Earnings Report?
Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 09/08 15:30
Why IMARA Jumped Around 75%; Here Are 54 Biggest Movers From Yesterday
Gainers
Benzinga · 09/08 09:26
Amylyx drives Reta, Ardelyx higher ahead of AdCom decision on ALS drug
The shares of clinical-stage biopharma companies Reata Pharmaceuticals (NASDAQ:<a href="https://seekingalpha.com/symbol/RETA?utm_medium=referral&utm_source=webull.com" title="Reata Pharmaceuticals, Inc." target=...
Seekingalpha · 09/07 17:41
Reata Pharmaceuticals, Inc. (RETA) Up 4.7% Since Last Earnings Report: Can It Continue?
Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 09/07 15:30
Reata Pharmaceuticals Announces Participation in the Citi 17th Annual BioPharma Conference
PLANO, Texas, September 06, 2022--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) ("Reata," the "Company," or "we"), a clinical-stage biopharmaceutical company, today announced that management will participate in investor meetings at the Citi 17th Annual BioPha...
Business Wire · 09/06 20:51
Amylyx plunges 28% after FDA briefing documents on ALS drug
Amylyx Pharmaceuticals (NASDAQ:AMLX), a company focu...
Seekingalpha · 09/02 16:17
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Benzinga · 08/31 12:07
More
About RETA
Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on identifying, developing, and commercializing therapies. The Company is also focused on providing small-molecule therapeutics with mechanisms of action for the treatment of severe, life-threatening diseases with therapies. Its lead programs are omaveloxolone in a neurological disease called Friedreich’s ataxia (FA) and bardoxolone methyl (bardoxolone) in rare forms of chronic kidney disease (CKD). The Company’s lead product candidates activate the transcription factor Nrf2 to normalize mitochondrial function, restore redox balance, and resolve inflammation. It is also developing RTA 901, the lead product candidate from its Hsp90 modulator program, in neurological indications. Omaveloxolone and bardoxolone are Nuclear factor-erythroid factor 2-related factor 2 (Nrf2) activators that selectively bind to Keap1, a protein that governs the activity of Nrf2 in response to cellular stress.

Webull offers kinds of Reata Pharmaceuticals Inc stock information, including NASDAQ:RETA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RETA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RETA stock methods without spending real money on the virtual paper trading platform.